...
机译:SLE患者的血清DNase I,可溶性Fas / FasL水平和细胞表面Fas表达:hrDNase I缺乏疗效的可能解释
1Department of Clinical and Experimental Medicine, Section of Internal Medicine, University of Verona, 37134 Verona, Italy 2Institute G. Gaslini, Department of Immunology, Genova, Italy 3Department of Experimental Medicine, Section of Histology, University of Genova, Genova, Italy 4Department of Clinical and Experimental Medicine, Section of Rheumatology, University of Perugia, Perugia, Italy 5Department of Clinical and Experimental Medicine, Section of Hematology, University of Verona, Verona, Italy 6Department of Internal Medicine, Section of Clinical Immunology, University of Pisa, Pisa, Italy;
机译:SLE患者的血清DNase I,可溶性Fas / FasL水平和细胞表面Fas表达:这可能是hrDNase I治疗无效的原因。
机译:ADAM10,Fas,FasL和可溶性FasL在口腔鳞状细胞癌(OSCC)患者中的表达及其与临床病理参数的关系
机译:患有口腔鳞状细胞癌(OSCC)患者的Adam10,Fas,FasL和可溶性FasL的表达及其与临床病理参数的关联
机译:非小细胞肺癌中Fas,FasL,p53和bcl-2表达的关系
机译:胃癌细胞系缺乏FasL配体(FasL)表达但通过FasL非依赖性途径杀死T细胞
机译:SLE患者血清DNase I,可溶性Fas / FasL水平和细胞表面FAS表达:对缺乏HRDNase I治疗的可能解释